RP20170125_1023_LowRez (2)
SVP BD and Alliance Management
Cambridge Massachusetts        UNITED STATES
Message Notes
Jennifer has 20 years operating experience in the biopharmaceutical industry. In June of 2015, she joined Intellia Therapeutics, a company focused on developing curative medicines using the promise of CRISPR/CAS9 genome editing technology. Prior to joining Intellia, Jennifer a held a variety of business development and commercial roles supporting the rare disease business at Shire Pharmaceuticals. Before joining Shire in 2006, Jennifer held a variety of commercial roles in at Millennium Pharmaceuticals; most notably as the Product Manager for the US launch of VELCADE®. Jennifer received her B.S. in Biology from the Massachusetts Institute of Technology, earned a Ph.D. in Developmental Biology at the Stanford University School of Medicine, and was awarded her MBA by Northeastern University.
Add to myBIO Planner Notes
None yet.